ADARx Pharmaceuticals, Inc.
NASDAQ:ADRXBiotechnology
+$0.13 today
- Market cap
- $1.53B
- Beta
- 0.00
Volume 0.70M
Average 1.06M
Fair Value & DCF
Compare our fair value with your own assumptions
Intrinsic Alpha selects a valuation method suited to the business. Use the calculator below to build an independent scenario with your preferred cash-flow basis.
ADARx Pharmaceuticals, Inc.
NASDAQ:ADRX
Intrinsic Alpha fair value
Locked
Current Price
$13.82
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Build your own valuation
Test an independent scenario and compare it with Intrinsic Alpha's estimate.
Sign in to use the DCF calculator
Free accounts get 5 valuations per week. Upgrade for more.
Growth Analysis
Historical CAGR & forward analyst estimates
Estimates & History
Historical data and analyst estimates. Solid bars are actuals; dashed-border bars are future estimates.
No data available for this stock.
Competitor Valuations
Peer stocks ranked by intrinsic value status
| Company | Market Cap | Price | Valuation | P/E | 1Y Return |
|---|---|---|---|---|---|
Stoke Therapeutics, Inc. NASDAQ:STOK | $1.75B | $26.68 | Undervalued | -11.1 | -8.68% |
Silence Therapeutics plc NASDAQ:SLN | $936.65M | $19.83 | Not rated | -3.9 | +193.33% |
MeiraGTx Holdings plc NASDAQ:MGTX | $881.67M | $9.18 | Not rated | -7.4 | +9.16% |
Prime Medicine, Inc. NASDAQ:PRME | $774.48M | $4.27 | Not rated | -2.8 | +8.17% |
Wave Life Sciences Ltd. NASDAQ:WVE | $617.33M | $3.13 | Not rated | -6.6 | -60.06% |
Benitec Biopharma Inc. NASDAQ:BNTC | $315.40M | $9.04 | Not rated | -12.3 | -39.76% |
Arcturus Therapeutics Holdings Inc. NASDAQ:ARCT | $240.96M | $8.36 | Not rated | -2.7 | +20.39% |
ProQR Therapeutics N.V. NASDAQ:PRQR | $198.98M | $1.41 | Not rated | -3.8 | -44.71% |
Atrium Therapeutics, Inc. NASDAQ:RNA | $128.46M | $7.51 | Not rated | -3.3 | — |
Continue the stock analysis
Jump to another research area for this company.